The observation that anti-CD40 mAbs enable CD8+ T cell independent tumor cell killing, prompted the use of a fully humanized CD40 agonist mAb (CP-870.893) in a phase I clinical trial, showing that its combination with gemcitabine activates antitumor immune responses (188). Here, CD8A is linked to neoplasm.